306 related articles for article (PubMed ID: 31400577)
21. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
22. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy.
Opala AR; Kennedy K; Baker SK
Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669
[TBL] [Abstract][Full Text] [Related]
23. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy.
Lucke IM; Adrichem ME; Wieske L; van der Kooi AJ; Verhamme C; van Schaik IN; Eftimov F
J Neurol Sci; 2019 Feb; 397():141-145. PubMed ID: 30623818
[TBL] [Abstract][Full Text] [Related]
24. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
[TBL] [Abstract][Full Text] [Related]
25. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
[TBL] [Abstract][Full Text] [Related]
27. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes.
Alabdali M; Abraham A; Alsulaiman A; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
J Neurol Sci; 2017 Jan; 372():223-227. PubMed ID: 28017218
[TBL] [Abstract][Full Text] [Related]
29. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy.
Clerici AM; Nobile-Orazio E; Mauri M; Squellati FS; Bono GG
BMC Neurol; 2017 Jul; 17(1):127. PubMed ID: 28668085
[TBL] [Abstract][Full Text] [Related]
30. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment.
Pegat A; Boisseau W; Maisonobe T; Debs R; Lenglet T; Psimaras D; Azoulay-Cayla A; Fournier E; Viala K
J Peripher Nerv Syst; 2020 Jun; 25(2):162-170. PubMed ID: 32364302
[TBL] [Abstract][Full Text] [Related]
31. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
[TBL] [Abstract][Full Text] [Related]
32. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
33. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
Hahn AF; Bolton CF; Zochodne D; Feasby TE
Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
[TBL] [Abstract][Full Text] [Related]
36. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
37. Motor-dominant chronic inflammatory demyelinating polyneuropathy.
Kimura A; Sakurai T; Koumura A; Yamada M; Hayashi Y; Tanaka Y; Hozumi I; Yoshino H; Yuasa T; Inuzuka T
J Neurol; 2010 Apr; 257(4):621-9. PubMed ID: 20361294
[TBL] [Abstract][Full Text] [Related]
38. Electrophysiologic correlations with clinical outcomes in CIDP.
Bril V; Banach M; Dalakas MC; Deng C; Donofrio P; Hanna K; Hartung HP; Hughes RA; Katzberg H; Latov N; Merkies IS; Van Doorn PA;
Muscle Nerve; 2010 Oct; 42(4):492-7. PubMed ID: 20665514
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
[TBL] [Abstract][Full Text] [Related]
40. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
